Redeye provides a research update following the Q4 report recently published by Initiator Pharma. Although OPEX has increased as a direct result of the recently initiated clinical activities, the financials in the report did not contain any major surprises. Importantly, the company announced in the report that the first patient in the phase IIa study with pudafensine in vulvodynia has now been dosed. With topline results expected in late 2026, and bolstered by a strengthened IP protection, we have a positive outlook on the company’s year ahead.
LÄS MER
